Advertisement
Screener

Elite Pharmaceuticals, Inc. (ELTP) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2.0 / 5 stars · 41/105 Roast Me

Elite Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

Elite Pharmaceuticals, Inc. (ELTP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 90.00 thousand shares for the 12-month period ending 2025-03-31, per its 10-K filed 2025-06-30.

Financial Statements › Shareholders' Equity

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2025-06-30

  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 0.00 shares, a 100.00% decline year-over-year.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-31 was 300.00K shares, a 97.38% decline year-over-year.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-12-31 was 100.00K shares, a 96.67% decline year-over-year.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-03-31 was 11.43M shares, a 5615.00% increase year-over-year.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 90.00K shares, a 97.95% decline from fiscal 2024.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 4.40M shares, a 71.67% decline from fiscal 2023.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 15.53M shares, a 3006.00% increase from fiscal 2022.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 500.00K shares, a 16.67% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month
2025-03-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-30
90.00K shares
10-K · filed 2025-06-30
2024-12-3190.00K shares
10-Q · filed 2025-02-13
2024-03-31300.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-01
400.00K shares
derived: sum of 2 quarters · filed 2024-07-01
4.40M shares
10-K · filed 2024-07-01
2023-12-31100.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-14
4.10M shares
10-Q · filed 2024-02-14
2023-09-304.00M shares
10-Q · filed 2023-11-14
2023-03-3111.43M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-29
14.43M shares
derived: sum of 2 quarters · filed 2023-06-29
14.43M shares
derived: sum of 3 quarters · filed 2023-06-29
15.53M shares
10-K · filed 2023-06-29
2022-12-313.00M shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-14
3.00M shares
derived: sum of 2 quarters · filed 2023-02-14
4.10M shares
10-Q · filed 2023-02-14
4.30M shares
derived: sum of 4 quarters · filed 2023-06-29
2022-09-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14
1.10M shares
10-Q · filed 2022-11-14
1.30M shares
derived: sum of 3 quarters · filed 2023-06-29
1.30M shares
derived: sum of 4 quarters · filed 2023-06-29
2022-06-301.10M shares
10-Q · filed 2022-08-15
1.30M shares
derived: sum of 2 quarters · filed 2023-06-29
1.30M shares
derived: sum of 3 quarters · filed 2023-06-29
1.30M shares
derived: sum of 4 quarters · filed 2023-06-29
2022-03-31200.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-29
200.00K shares
derived: sum of 2 quarters · filed 2023-06-29
200.00K shares
derived: sum of 3 quarters · filed 2023-06-29
500.00K shares
10-K · filed 2023-06-29
2021-12-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-14
0.00 shares
derived: sum of 2 quarters · filed 2022-02-14
300.00K shares
10-Q · filed 2022-02-14
2021-09-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-15
300.00K shares
10-Q · filed 2021-11-15
2021-06-30300.00K shares
10-Q · filed 2021-08-16
2021-03-31600.00K shares
10-K · filed 2022-06-29
2020-03-31115.00K shares
10-K · filed 2021-06-14
2018-06-300.00 shares
10-Q · filed 2018-08-09
80.00K shares
derived: sum of 2 quarters · filed 2019-06-21
80.00K shares
derived: sum of 3 quarters · filed 2019-06-21
340.00K shares
derived: sum of 4 quarters · filed 2019-06-21
2018-03-3180.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-06-21
80.00K shares
derived: sum of 2 quarters · filed 2019-06-21
340.00K shares
derived: sum of 3 quarters · filed 2019-06-21
640.00K shares
10-K · filed 2019-06-21
2017-12-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-02-09
260.00K shares
derived: sum of 2 quarters · filed 2018-02-09
560.00K shares
10-Q · filed 2018-02-09
2017-09-30260.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-11-09
560.00K shares
10-Q · filed 2017-11-09
2017-06-30300.00K shares
10-Q · filed 2017-08-09
2016-12-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-02-09
870.00K shares
derived: sum of 2 quarters · filed 2017-02-09
870.00K shares
10-Q · filed 2017-02-09
2016-09-30870.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-11-09
870.00K shares
10-Q · filed 2016-11-09
2016-06-300.00 shares
10-Q · filed 2016-08-09
2016-03-31360.00K shares
10-K · filed 2016-06-15
2015-03-312.59M shares
10-K · filed 2016-06-15
2014-03-313.00M shares
10-K · filed 2016-06-15
2013-03-31985.00K shares
10-K · filed 2014-06-30
2012-03-310.00 shares
10-K · filed 2013-06-21
2010-03-311.00M shares
10-K · filed 2014-06-30